Evidence map›Paper›PMID 38931449›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease.

Yiting Zhao, Man Lin, Fengguang Zhai, Jun Chen, Xiaofeng Jin

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. The Roles of E3 Ubiquitin Ligases in Cerebral Ischemia-Reperfusion Injury.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yiting ZhaoDepartment of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, China.
Man LinDepartment of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, China.
Fengguang ZhaiZhejiang Key Laboratory of Pathophysiology, Department of Biochemistry and Molecular Biology, Health Science Center of Ningbo University, Ningbo 315211, China.
Jun ChenDepartment of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, China.
Xiaofeng JinDepartment of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, China.

Funding

The Fundamental Research Funds for the Provincial Universities of Zhejiang SJLZ2022004The Medical and health science and Technology project of Zhejiang Province 2019337934The National Natural Science Foundation of China 32279821The Natural Science Foundation of Ningbo 2021J065
6 · The paper itself

Abstract

Parkinson's disease (PD) is a prevalent neurodegenerative disorder among the elderly population. The pathogenesis of PD encompasses genetic alterations, environmental factors, and age-related neurodegenerative processes. Numerous studies have demonstrated that aberrant functioning of the ubiquitin-proteasome system (UPS) plays a crucial role in the initiation and progression of PD. Notably, E3 ubiquitin ligases serve as pivotal components determining substrate specificity within UPS and are intimately associated with the regulation of various proteins implicated in PD pathology. This review comprehensively summarizes the mechanisms by which E3 ubiquitin ligases and deubiquitinating enzymes modulate PD-associated proteins and signaling pathways, while exploring the intricate relationship between UPS dysfunctions and PD etiology. Furthermore, this article discusses recent research advancements regarding inhibitors targeting PD-related E3 ubiquitin ligases.

Indexed as

deubiquitination enzymeE3 ligaseParkinson’s diseasePD etiologyubiquitin-proteasome system (UPS)

Identifiers

PMID38931449
PMCPMC11207014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.